Alnylam Pharmaceuticals, Inc. (ALNY)
266.65
+20.54
(+8.35%)
USD |
NASDAQ |
Sep 02, 15:21
Alnylam Pharmaceuticals Research and Development Expense (Annual) : 1.320B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 1.320B |
| December 31, 2024 | 1.126B |
| December 31, 2023 | 1.004B |
| December 31, 2022 | 883.02M |
| December 31, 2021 | 792.16M |
| December 31, 2020 | 654.82M |
| December 31, 2019 | 655.11M |
| December 31, 2018 | 505.42M |
| December 31, 2017 | 390.64M |
| December 31, 2016 | 382.39M |
| December 31, 2015 | 276.50M |
| December 31, 2014 | 190.25M |
| Date | Value |
|---|---|
| December 31, 2013 | 112.96M |
| December 31, 2012 | 86.57M |
| December 31, 2011 | 99.30M |
| December 31, 2010 | 106.38M |
| December 31, 2009 | 108.73M |
| December 31, 2008 | 96.88M |
| December 31, 2007 | 117.79M |
| December 31, 2006 | 49.80M |
| December 31, 2005 | 35.32M |
| December 31, 2004 | 24.60M |
| December 31, 2003 | 13.10M |
| December 31, 2002 | 3.342M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ionis Pharmaceuticals, Inc. | 913.18M |
| BridgeBio Pharma, Inc. | 451.95M |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Pfizer Inc. | 10.25B |